´ëÇÑÇ÷¾×ÇÐȸ Á¦31Â÷ ¸²ÇÁÁ¾¿¬±¸È¸ Ãß°è Á¤±â ½ÉÆ÷Áö¾ö : 2022-10-22±³À°ÀÏÀÚ : 2022-10-22
±³À°Àå¼Ò : ¾çÀç aT¼¾ÅÍ 3Ãþ ¼¼°è·Î
±³À°ÁÖÁ¦ :
´ëÇÑÇ÷¾×ÇÐȸ Á¦31Â÷ ¸²ÇÁÁ¾¿¬±¸È¸ Ãß°è Á¤±â ½ÉÆ÷Áö¾öÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ¸²ÇÁÁ¾¿¬±¸È¸
´ã´çÀÚ : ±èÇýÁø
¿¬¶ôó : 02-516-6581
À̸ÞÀÏ :
hematology@kams.or.kr ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 80¸í
Èñ¸ÁÆòÁ¡ : 5Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 5 ½Ã°£ 30ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 10-22 10:00~10:40 Overview of EBV(epstein-barr virus)-associated lymphoid malignancies ±èÁ¤Çö(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 10-22 10:40~11:20 How to treat ENKTL(Extranodal NK/T Cell Lymphoma) patients ±è¼®Áø(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 10-22 11:20~12:00 What should we do for chronic active EBV( epstein-barr virus) infection? ÃÖÀ±¼®(¾ÆÁÖÀÇ´ë)
±³À°½Ã°£ 10-22 12:00~12:30 Application of CAR-T/NK cell therapy for T-cell lymphomas ÀÌÁØÈ£(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 10-22 13:30~14:10 Pathology: how to differentiate G3A, G3B FL(follicular lymphomas), and DLBCL(diffuse large B-cell lymphoma) ¹éÁøÈ£(¼¿ïÀÇ´ë)
±³À°½Ã°£ 10-22 14:10~14:50 How to treat G3A and G3B FL(follicular lymphomas): induction and maintenance? Á¶Àçö(¿ï»êÀÇ´ë)
±³À°½Ã°£ 10-22 14:50~15:30 How to treat BL(burkitt Lymphoma) based on recent data Á¶Çö¼ö(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 10-22 15:40~16:20 COVID-19: active and passive immunization and treatment of COVID-19 in lymphoma patients °íÀçÈÆ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 10-22 16:20~16:40 T cell engagers vs. CAR-T for relapsed/refractory DLBCLdiffuse large B-cell lymphoma) À¯ÄèÇÑ(°¡ÃµÀÇ´ë)